A population-based cohort study from the Netherlands Cancer Registry including 1155 HR-positive/HER2-positive BC patients reported a significant benefit from AI over TAM in perimenopausal patients (age <45 to ≤55 years as a proxy), a numerical benefit in postmenopausal patients (age >55 years), and a lack of benefit for premenopausal patients (age ≤45 years)28. Here, ERBB2 is linked to breast cancer.